SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
Clinical Prior Authorization Criteria Revisions Implement for Medicaid Fee-for-Service on October 26
Date: October 5, 2022 Attention: All Providers Subject: Effective Date: October 26, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Texas Children Health Plan (TCHP) will revise the clinical prior authorization criteria for the Anxiolytics and Sedative/Hypnotics (ASH), Attention Deficit Disorder/Attention-Deficit Hyperactivity Disorder (ADD/ADHD), and Qelbree (also within the ADD/ADHD Medications document) prior authorizations based on recent U.S. Food and Drug Administration (FDA) approved indications.
How this impacts providers: Effective October 26, 2022, the following revisions will be implemented:
Anxiolytics and Sedative/Hypnotics prior authorization criteria
ICD-10 code: F13.90 "Sedative, Hypnotic, or Anxiolytic Use, Unspecified, Uncomplicated" is no longer considered a diagnosis of drug abuse
ADD/ADHD clinical prior authorization criteria
New drugs were added to the clinical prior authorization criteria: Amphetamine extended release (ER) 1.25 mg/mL suspension, Methylphenidate extended release (ER) capsules and Methylphenidate long acting (LA)
Age check for Qelbree has been expanded to 6 years and older
For patients greater than or equal to 18 years prescribed non stimulants agents, a diagnosis of ADD/ADHD is no longer required.
